Physician profile
Freidy A Eid
NPI 1629205356
$12,501.43
in general payments reported to CMS, 2019-2025
28 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $1,393 · 2021: $1,756 · 2022: $2,622 · 2023: $1,150 · 2024: $4,088 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,912 · Travel and Lodging: $1,920 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,911.54 |
| Travel and Lodging | $1,920.41 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,603.18 | 2019-2025 | Aveir, Jot Dx, Assurity |
| Medtronic, INC. | $2,876.39 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan |
| Medtronic Vascular, INC. | $886.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.76 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $517.31 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $298.84 | 2021-2025 | Camzyos |
| Cvrx, INC. | $214.46 | 2021-2025 | Barostim Neo System |
| Boston Scientific Corporation | $208.21 | 2019-2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $193.90 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $171.03 | 2022-2023 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $158.70 | 2019-2024 | |
| Philips North America LLC | $103.32 | 2019-2025 | Extended Holter |
| Biotronik INC. | $95.10 | 2019-2020 | |
| Pfizer INC. | $86.03 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.86 | 2019-2025 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $62.52 | 2024 | Wegovy, Ozempic |
| Amgen INC. | $46.49 | 2022-2024 | Repatha |
| Amarin Pharma, INC. | $45.17 | 2021 | |
| Kestra Medical Technology Services, INC. | $28.53 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $27.85 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $23.26 | 2021 | |
| Surmodics, INC. | $23.05 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy, Pounce Thrombectomy System |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Edwards Lifesciences Corporation | $16.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.23 | 2021 | |
| Bridgebio Pharma, INC. | $14.62 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $13.91 | 2024 | |
| Bardy Diagnostics, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freidy Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.